FDA will also conduct its own evaluation studies. The Agency will explore and identify relationships between FDA actions and accomplishments under the CGMP Initiative, and subsequent improvements in public health. Examples of such actions and accomplishments are: the adoption of quality systems by industry; the use of risk factors to select inspection sites; and the review of the warning letter process. The studies will attempt to link such activities to their impact on regulated industry and on public health-related outcomes (e.g., improvement in drug quality). FDA also plans to validate the CGMP Initiative’s contributions to the Agency’s longterm goals and mission.